Evidence map›Paper›PMID 37259925›Full record

ArticleMolecular systems biology2023

A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability.

Amandine Moretton, Savvas Kourtis, Antoni Gañez Zapater, Chiara Calabrò, Maria Lorena Espinar Calvo, Frédéric Fontaine, Evangelia Darai, Etna Abad Cortel, Samuel Block, Laura Pascual-Reguant and 7 more

Open access · goldAbstract read
In one paragraph

Article in Molecular systems biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Peroxiredoxin 1 safeguards the nucleolar genome from oxidative damage.bioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. A new perspective on iron-dependent cell death: PRDX-1-mediated ferroptosis in tumor cells.Apoptosis : an international journal on programmed cell death · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Amandine Moretton *Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1700-3999
Savvas Kourtis *Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-3800-0853
Antoni Gañez Zapater *Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-6852-4834
Chiara Calabrò *Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Maria Lorena Espinar CalvoCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-3881-3886
Frédéric FontaineCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Evangelia DaraiCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Etna Abad CortelDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Samuel BlockKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Laura Pascual-ReguantCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-2361-1392
Natalia Pardo-LorenteCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-1847-4223
Ritobrata GhoseCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-9166-6849
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6702-4192
Ana JanicDepartment of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID 0000-0002-4200-2560
André C MüllerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Joanna I LoizouCenter for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1853-0424
Sara SdelciCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-1330-4364
Centre for Genomic Regulation · ESAustrian Academy of Sciences · ATUniversitat Pompeu Fabra · ESComprehensive Cancer Center Vienna · ATDana-Farber Cancer Institute · USMassachusetts Institute of Technology · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
NCI NIH HHS P30 CA014051NCI NIH HHS R35 CA242379
6 · The paper itself

Abstract

While cellular metabolism impacts the DNA damage response, a systematic understanding of the metabolic requirements that are crucial for DNA damage repair has yet to be achieved. Here, we investigate the metabolic enzymes and processes that are essential for the resolution of DNA damage. By integrating functional genomics with chromatin proteomics and metabolomics, we provide a detailed description of the interplay between cellular metabolism and the DNA damage response. Further analysis identified that Peroxiredoxin 1, PRDX1, contributes to the DNA damage repair. During the DNA damage response, PRDX1 translocates to the nucleus where it reduces DNA damage-induced nuclear reactive oxygen species. Moreover, PRDX1 loss lowers aspartate availability, which is required for the DNA damage-induced upregulation of de novo nucleotide synthesis. In the absence of PRDX1, cells accumulate replication stress and DNA damage, leading to proliferation defects that are exacerbated in the presence of etoposide, thus revealing a role for PRDX1 as a DNA damage surveillance factor.

Indexed as

Aspartic AcidPeroxiredoxinsDNA DamageHumansOxidative StressReactive Oxygen SpeciesAspartic AcidPeroxiredoxinsPRDX1 protein, humanReactive Oxygen Speciesaspartate metabolismDNA damage responseelectron transport chainPeroxiredoxin 1reactive oxygen species scavenging

Identifiers

PMID37259925
PMCPMC10333845
OpenAlexW4378952904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.